Back to Search Start Over

MiR-200c-3p expression may be associated with worsening of the clinical course of patients with COVID-19.

Authors :
Pimenta R
Viana NI
Dos Santos GA
Candido P
Guimarães VR
Romão P
Silva IA
de Camargo JA
Hatanaka DM
Queiroz PGS
Teruya A
Echenique L
Besen BAMP
Leite KRM
Srougi V
Srougi M
Reis ST
Source :
Molecular biology research communications [Mol Biol Res Commun] 2021 Sep; Vol. 10 (3), pp. 141-147.
Publication Year :
2021

Abstract

COVID-19 represents a public health emergency, whose mechanism of which is not fully understood. It is speculated that microRNAs may play a crucial role in host cells after infection by SARS-CoV-2. Thus, our study aimed to analyze the expression of miR-200c-3p in saliva samples from patients with COVID-19. One handred eleven samples from patients with COVID-19 were divided into 4 groups. Group I: 39 patients negative for Covid-19; Group II: 37 positive and symptomatic patients, with no indication of hospitalization; Group III: 21 patients with respiratory disorders (hospitalized); Group IV: 14 patients with severe conditions (oxygen therapy). The expression levels of miR-200c-3p were determined using qPCR. We found greater expression of miR-200c-3p in patients in group IV ( p <0.0001), and also verified that patients aged ≥42 years had a higher expression of this miR ( p =0.013). Logistic regression analysis revealed that the expression of miR-200c-3p and systemic arterial hypertension are factors independently associated with patients in group IV ( p <0.0001). Our results suggest that miR-200c-3p is a predictor of severity independent of COVID-19 risk factors, which could represent a way of screening patients affected by SARS-CoV-2.<br />Competing Interests: The authors declare that they have no conflict of interests.

Details

Language :
English
ISSN :
2345-2005
Volume :
10
Issue :
3
Database :
MEDLINE
Journal :
Molecular biology research communications
Publication Type :
Academic Journal
Accession number :
34476267
Full Text :
https://doi.org/10.22099/mbrc.2021.40555.1631